Teva Pharmaceuticals
TEVA NYSE· Pharmaceuticals
Last close · Oct 26, 2026
$39.95
KIRA · Stoqly’s AI analyst, in plain words
- Teva Pharmaceuticals had $17.3B of revenue in fiscal 2025, up 4.3% on the year before. Over five years, revenue changed +0.7% a year on average.
- Its operating margin was 12.5%, up 14.3 pts: of every 100 in sales, about 13 is left after running the business.
- Teva Pharmaceuticals made $1.4B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 37.3% a year.
- Free cash flow was $1.1B in fiscal 2025, 6.7% of revenue.
- Teva Pharmaceuticals returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 2.8%.
- Teva Pharmaceuticals owes $13.3B more than it holds in cash, about 4.2 years of operating profit.
Market cap
$46.5B
P/E
66.6x
Revenue
$17.3B
Net income
$1.4B
Free cash flow
$1.1B
Operating margin
12.5%
Teva Pharmaceuticals in 30 seconds · fiscal 2025
Are sales growing?
+4.3%
Only a little. Sales grew 4.3% last year.
Does it make a profit?
8.2%
A little. It keeps 8.2% of every sale as profit.
Does profit turn into cash?
6.7%
Partly. 6.7% of sales ends up as free cash.
Is debt under control?
4.2x
Heavy. Repaying its debt would take 4.2 years of operating profit.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
66.6x
One share costs 66.6 times its yearly profit per share. Typical for its sector: 27.9x.
What Teva Pharmaceuticals does
Teva makes and sells medicines in two groups: generics, which are lower-cost copies of drugs whose patents have expired, along with biosimilars and over-the-counter products, and its own branded medicines. It is based in Israel, has about 34,000 employees across 57 markets, and has a large presence in the United States and Europe. Its generics are sold mainly to retail drug chains, mail-order distributors and wholesalers. It reports three segments, each selling its full range in its region: United States, Europe, and International Markets, which covers more than 35 other countries, including Canada, Israel, Russia and parts of Latin America. Its branded medicines focus on the central nervous system, meaning the brain and nerves. They include Austedo for movement disorders, Ajovy for migraine prevention, Uzedy for schizophrenia and Copaxone for multiple sclerosis. It also has branded respiratory and cancer drugs and biosimilars.
Biggest risks, in its own words
- Generic medicines are a large part of its business, with pricing pressure, strong competition and a concentrated customer base.
- Delays in launching new generic products and difficulty taking advantage of biosimilar opportunities.
- Generic or biosimilar rivals that could cut sales of its own branded medicines.
- Its need to develop and sell additional products and to protect its patents and other intellectual property.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 3, 2026
- Legal name
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- CIK
- 0000818686
Teva Pharmaceuticals · TEVA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B |
| Revenue growth | −4.7% | −6.0% | 6.2% | 4.4% | 4.3% |
| Gross margin | 47.8% | 46.7% | 48.3% | 48.7% | 51.8% |
| Operating margin | 10.8% | −14.7% | 2.7% | −1.8% | 12.5% |
| Net income | $417M | −$2.4B | −$559M | −$1.6B | $1.4B |
| Net margin | 2.6% | −16.4% | −3.5% | −9.9% | 8.2% |
| Diluted EPS | $0.38 | −$2.20 | −$0.50 | −$1.45 | $1.21 |
| Cash | |||||
| Cash from operations | $798M | $1.6B | $1.4B | $1.2B | $1.6B |
| Capital expenditure | $562M | $548M | $526M | $498M | $501M |
| Free cash flow | $236M | $1.0B | $842M | $749M | $1.1B |
| FCF margin | 1.5% | 7.0% | 5.3% | 4.5% | 6.7% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 1.1% | 0.3% | 0.8% | 1.1% | 2.8% |
| Debt and strength | |||||
| Cash and short-term investments | $2.2B | $2.8B | $3.2B | $3.3B | $3.6B |
| Debt incl. finance leases | $23.1B | $21.2B | $19.9B | $17.8B | $16.8B |
| Shareholders' equity | $10.3B | $7.8B | $7.5B | $5.4B | $7.9B |
| Net debt / EBITDA | 6.9x | — | 10.5x | 19.2x | 4.2x |
| Current ratio | 1.1x | 1.1x | 1.0x | 1.0x | 1.0x |
| Interest coverage | 1.9x | −2.4x | 0.4x | −0.3x | 2.4x |
| Returns and quality | |||||
| Return on capital | 3.5% | −5.9% | 1.3% | −1.1% | 10.5% |
| Return on equity | 4.1% | −27.1% | −7.3% | −25.5% | 21.2% |
| Piotroski F-score | 8 | 3 | 6 | 5 | 8 |
| Altman Z'' | 0.1 | −1.0 | −0.7 | −1.2 | −0.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$113M
14 insiders
Of sales under plans
61%
$69.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Teva Pharmaceuticals · TEVA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceuticals TEVA | $46.5B | 4.3% | 12.5% | 6.7% | 10.5% | 66.6x | 8 |
| Viatris VTRS | $21.3B | −3.0% | −18.6% | 13.6% | −7.1% | — | 4 |
| Bausch Health Companies BHC | $2.4B | 6.7% | 17.7% | 9.8% | 4.5% | — | 7 |
| Zoetis ZTS | $33.8B | 2.3% | — | 24.1% | 29.3% | 13.3x | 8 |
| Bristol Myers Squibb BMY | $126.2B | −0.2% | — | 26.7% | 15.2% | 13.6x | 8 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $39.95 a share, the company is worth $46.5B: 66.6 times its earnings of the last four quarters.
Teva Pharmaceuticals grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 2 of 2.
Source: SEC EDGAR XBRL filings (CIK 0000818686). Data updated October 23, 2026. For information only — not investment advice. Check the original filings before relying on any figure.